BIOADAPTOR RCT
n=445
An RCT that confirms the durability of bioadaptor treatment benefit following device unlocking through long-term follow-up compared to a contemporary DES.
The study showed:
- 66% reduction in TLF at 4 years vs. DES (p=0.020 for superiority)
- Significant reduction in cardiovascular death (p=0.037 for superiority)
- 16.7% increase in blood flow
- -9% plaque volume regression in lipid-rich lesions vs. +10% increase for DES
